Evaxion and MSD have been collaborating on EVX-B3 since 2023. Also in 2023, MSD, through its Global Health Innovation Fund (MGHIF), led a private placement round of financing for Evaxion to become ...

Evaxion Biotech shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of Merck & Co ...

On Wednesday, December 12, 2018, Brazil's Butantan Institute signed a collaboration agreement with Merck Sharp & Dohme (MSD) to develop dengue vaccines. The São Paulo State research institution ...

SINGAPORE, October 21, 2011 - MSD, known as Merck in the United States and Canada, and the Singapore Economic Development Board today jointly announced the signing of a new agreement under which ...

Under the terms of the agreement, PeptiDream will receive an upfront payment from MSD and be eligible for payments based on the achievement of specified development, regulatory, and commercial ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development ...

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on ...

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on ...